Product Images Gabapentin
View Photos of Packaging, Labels & Appearance
- Creatinine clearance - gabapentin fig1
- Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
- Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig3
- Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
- Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
- PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 600 mg (100 Tablets Bottle) - gabapentin fig6
- PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 800 mg (100 Tablets Bottle) - gabapentin fig7
- Chemical Structure - gabapentin str
Product Label Images
The following 8 images provide visual information about the product associated with Gabapentin NDC 65862-523 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Creatinine clearance - gabapentin fig1
This text looks like a formula for calculating a medical value called "Lt" using the age and weight of a patient along with their creatinine levels. However, the text is incomplete and some important information might be missing, as there are no units for the weight or creatinine values. Therefore, it's not possible to generate a useful description with this text alone.*
Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
The text presents a graph with the weekly mean pain scores observed in an ITT population during Study 1. The graph shows the scores for the placebo group and for the group taking Gabapentin at a dose of 300 mg per day. There is also some text indicating the names of days and people that are not relevant for the description.*
Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
Not available.*
Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
This is a graph showing the figures expressed as a difference from placebo by dosage and study for adjunctive therapy in patients 12 years of age with partial seizures. The daily dosage is shown in milligrams. No further information is given.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 600 mg (100 Tablets Bottle) - gabapentin fig6
Gabapentin Tablets, USP 600 mg is a medication distributed by Aurohindo Pharma USA, Inc. The tablets are made in India and contain Gabapentin USP at 600 mg. The usual dosage is mentioned in the package insert. The NDC of the medication is 65862-523-01. The medication is available only on prescription. The package has a separate medication guide for each patient. The code for the medication is TS/DRUGS/22/2009. The text does not contain any non-English characters.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 800 mg (100 Tablets Bottle) - gabapentin fig7
Gabapentin Tablets, USP are a medication available by prescription only. Each tablet has 800mg of Gabapentin USP and is sold in a bottle of 100 tablets. The medication guide provided separately should be given to each patient. The product is distributed by Aurobindo Pharma USA, Inc. and made in India. Store at 20° to 25°C (68° to 77°F). See package insert for full prescribing information. The code is TS/DRUGS/22/2009.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.